Literature DB >> 23091812

Type and cause of liver disease in Korea: single-center experience, 2005-2010.

Sang Soo Lee1, Young-Sang Byoun, Sook-Hyang Jeong, Yeo Myung Kim, Ho Gil, Bo-Young Min, Mun Hyuk Seong, Eun Sun Jang, Jin-Wook Kim.   

Abstract

BACKGROUND/AIMS: The aim of this study was to describe the types and causes of liver disease in patients from a single community hospital in Korea between April 2005 and May 2010.
METHODS: A cohort of patients who visited the liver clinic of the hospital during the aforementioned time period were consecutively enrolled (n=6,307). Consistent diagnostic criteria for each liver disease were set by a single, experienced hepatologist, and the diagnosis of all of the enrolled patients was confirmed by retrospective review of their medical records.
RESULTS: Among the 6,307 patients, 528 (8.4%) were classified as acute hepatitis, 3,957 (62.7%) as chronic hepatitis, 767 (12.2%) as liver cirrhosis, 509 (8.1%) as primary liver cancer, and 546 (8.7%) as a benign liver mass or other diseases. The etiologies in the acute hepatitis group in decreasing order of prevalence were hepatitis A (44.3%), toxic hepatitis (32.4%), other hepatitis viruses (13.8%), and cryptogenic hepatitis (9.1%). In the chronic hepatitis group, 51.2% of cases were attributed to viral hepatitis, 33.3% to nonalcoholic fatty liver disease, and 13.0% to alcoholic liver disease (ALD). Of the cirrhoses, 73.4% were attributable to viral causes and 18.1% to alcohol. Of the hepatocellular carcinoma cases, 86.6% were attributed to viral hepatitis and 11.6% to ALD. Among the benign tumors, hemangioma comprised 52.2% and cystic liver disease comprised 33.7%.
CONCLUSIONS: Knowledge of the current status of the type and cause of liver disease in Korea may be valuable as a basis for evaluating changing trends in liver disease in that country.

Entities:  

Keywords:  Diagnosis; Etiology, Korea; Liver disease

Mesh:

Year:  2012        PMID: 23091812      PMCID: PMC3467435          DOI: 10.3350/cmh.2012.18.3.309

Source DB:  PubMed          Journal:  Clin Mol Hepatol        ISSN: 2287-2728


  9 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Deaths: preliminary data for 2009.

Authors:  Kenneth D Kochanek; Jiaquan Xu; Sherry L Murphy; Arialdi M Miniño; Hsiang-Ching Kung
Journal:  Natl Vital Stat Rep       Date:  2011-03

Review 3.  Current status of hepatitis C virus infection in Korea.

Authors:  Dong Jin Suh; Sook-Hyang Jeong
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

4.  Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults.

Authors:  Seung H Park; Woo K Jeon; Sang H Kim; Hong J Kim; Dong I Park; Yong K Cho; In K Sung; Chong I Sohn; Dong K Keum; Byung I Kim
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

5.  [Practice guidelines for management of hepatocellular carcinoma 2009].

Authors: 
Journal:  Korean J Hepatol       Date:  2009-09

6.  [Recent etiology and clinical features of acute viral hepatitis in a single center of Korea].

Authors:  Hyung Min Kang; Sook Hyang Jeong; Jin Wook Kim; Donhun Lee; Chang Kyu Choi; Young Soo Park; Jin Hyuk Hwang; Nayoung Kim; Dong Ho Lee
Journal:  Korean J Hepatol       Date:  2007-12

Review 7.  Non-alcoholic fatty liver disease: the mist gradually clears.

Authors:  Nimantha Mark Wilfred de Alwis; Christopher Paul Day
Journal:  J Hepatol       Date:  2008-02-04       Impact factor: 25.083

Review 8.  Viral hepatitis C.

Authors:  Thierry Poynard; Man-Fung Yuen; Vlad Ratziu; Ching Lung Lai
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

9.  Socioeconomic costs of liver disease in Korea.

Authors:  Sunmi Lee; Woojin Chung; Kyung Rae Hyun
Journal:  Korean J Hepatol       Date:  2011-12
  9 in total
  22 in total

1.  Factors associated with significant liver fibrosis assessed using transient elastography in general population.

Authors:  Seng Chan You; Kwang Joon Kim; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Won Jae Lee; Kwang-Hyub Han
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 2.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

3.  Outcome analysis of hip or knee arthroplasty in patients with cirrhotic liver disease.

Authors:  Young-Jun Seol; Taek-Rim Yoon; Dong-Hyun Lee; Sun-Ho Lee; Kyung-Soon Park
Journal:  J Orthop       Date:  2017-01-04

4.  Feasibility of computed tomography texture analysis of hepatic fibrosis using dual-energy spectral detector computed tomography.

Authors:  ByukGyung Choi; In Young Choi; Sang Hoon Cha; Suk Keu Yeom; Hwan Hoon Chung; Seung Hwa Lee; Jaehyung Cha; Ju-Han Lee
Journal:  Jpn J Radiol       Date:  2020-07-14       Impact factor: 2.374

5.  Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.

Authors:  Jinmin Jung; Jae Hyun Kwon; Gi-Won Song; Eun-Young Tak; Vavara A Kirchner; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2018-04-20       Impact factor: 3.452

6.  HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.

Authors:  Jeong Han Kim; Yun Jung Choi; Hee Won Moon; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2013-12-28

7.  The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.

Authors:  Jun Jae Kim; Jeong Han Kim; Ja Kyung Koo; Yun Jung Choi; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2014-03-26

8.  Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Jeong Han Kim; Hee Won Moon; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2014-09-25

9.  The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.

Authors:  Jeong Han Kim; Sung Hyun Ahn; Soon Young Ko; Won Hyeok Choe; Kyun-Hwan Kim; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2016-06-15

Review 10.  Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition.

Authors:  Joo Ho Lee; Simonetta Friso; Sang-Woon Choi
Journal:  Nutrients       Date:  2014-08-21       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.